Serum pancreatic lipase immunoreactivity concentrations in dogs treated with potassium bromide and/or phenobarbital.
Potassium bromide, phenobarbital, or a combination of both is commonly used in the treatment of canine epilepsy. Several cases of clinical pancreatitis have been reported in dogs after treatment with potassium bromide, but the risk of elevated serum canine pancreatic lipase immunoreactivity concentrations in dogs treated with potassium bromide and/or phenobarbital has not previously been evaluated in a large group of dogs. This study suggests an increased risk for elevated serum canine pancreatic lipase immunoreactivity concentrations and possibly pancreatitis in dogs treated with potassium bromide or phenobarbital alone or in combination.
Steiner
Jörg M
JM
Texas A and M University.
Xenoulis
Panagiotis G
PG
Anderson
Joseph A
JA
Barr
A Catherine
AC
Williams
David A
DA
D000818:Animals; D000927:Anticonvulsants / Q000009:adverse effects* / Q000627:therapeutic use; D001965:Bromides / Q000009:adverse effects* / Q000627:therapeutic use; D004285:Dogs; D007118:Immunoassay / Q000379:methods / Q000662:veterinary*; D008049:Lipase / Q000378:metabolism*; D010179:Pancreas / Q000201:enzymology*; D010195:Pancreatitis / Q000139:chemically induced / Q000175:diagnosis / Q000662:veterinary; D010634:Phenobarbital / Q000009:adverse effects* / Q000627:therapeutic use; D017680:Potassium Compounds / Q000009:adverse effects* / Q000627:therapeutic use
D000927:Anticonvulsants; D001965:Bromides; D017680:Potassium Compounds; D008049:Lipase; C039004:potassium bromide; D010634:Phenobarbital